Cerus Corporation (CERS) Stock Analysis
Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $3.19: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that... Read more
Sell if holding. Engine safety override at $3.19: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.0/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -4.4%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.19: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $2.94. Score 6.0/10, moderate confidence.
Take-profit target: $3.97 (+25.6% upside). Prior stop was $2.94. Stop-loss: $2.94.
Quality below floor (3.1 < 4.0).
Cerus Corporation trades at a P/E of N/A (forward N/A). TrendMatrix value score: 8.7/10. Verdict: Sell.
9 analysts cover CERS with a consensus score of 4.2/5. Average price target: $5.
What does Cerus Corporation do?Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the...
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.